

# Anylam Pharmaceuticals, Inc.

## Reconciliation of Selected GAAP Measures to Non-GAAP Measures (In thousands)

	Three Months Ended		Twelve Months Ended	
	December 31, 2020	December 31, 2019	December 31, 2020	December 31, 2019
<b>Reconciliation of GAAP to Non-GAAP research and development:</b>				
GAAP Research and development	\$ 168,469	\$ 201,301	\$ 654,819	\$ 655,114
Less: Stock-based compensation expenses	(14,922)	(34,786)	(60,464)	(88,930)
Non-GAAP Research and development	<u>\$ 153,547</u>	<u>\$ 166,515</u>	<u>\$ 594,355</u>	<u>\$ 566,184</u>
<b>Reconciliation of GAAP to Non-GAAP selling, general and administrative:</b>				
GAAP Selling, general and administrative	\$ 166,291	\$ 156,277	\$ 588,420	\$ 479,005
Less: Stock-based compensation expenses	(19,354)	(31,411)	(79,409)	(85,911)
Less: Costs associated with the strategic financing collaboration	—	—	(1,083)	—
Less: Loss on contractual settlement	—	—	(650)	—
Less: Change in estimate of contingent liabilities	(10,216)	—	(38,216)	—
Non-GAAP Selling, general and administrative	<u>\$ 136,721</u>	<u>\$ 124,866</u>	<u>\$ 469,062</u>	<u>\$ 393,094</u>
<b>Reconciliation of GAAP to Non-GAAP operating loss:</b>				
GAAP operating loss	\$ (194,222)	\$ (298,073)	\$ (828,438)	\$ (939,431)
Add: Stock-based compensation expenses	34,276	66,197	139,873	174,841
Add: Costs associated with the strategic financing collaboration	—	—	1,083	—
Add: Loss on contractual settlement	—	—	650	—
Add: Change in estimate of contingent liabilities	10,216	—	38,216	—
Non-GAAP operating loss	<u>\$ (149,730)</u>	<u>\$ (231,876)</u>	<u>\$ (648,616)</u>	<u>\$ (764,590)</u>